BioSpace News Archive

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced preliminary data from its ongoing Phase 1 dose-escalation study of AB122.

Co-Founders Dr. Josh Axe and Jordan Rubin to provide healthcare practitioners education and premium collagen and bone broth supplements [09-November-2018] SCOTTSDALE, Ariz. , Nov. 9, 2018 /PRNewswire/ -- Natural Partners Fullscript, the premiere supplement dispensing solution for healthcare practitioners, announces the launch of Ancient Nutrition on the Natural Partne

Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH),

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced advancements in the company’s oncology program.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented updated results from the ongoing Phase 1/2 open-label extension (OLE) study of givosiran, an investigational RNAi therapeutic, targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP).

Halo Labs Inc. is pleased to report dispensary sales of approximately US$1.23 million for October 2018. This is an increase of approximately US$353,000 over September 2018. Approximately US$245,000 of the dispensary sales in October was derived from the Company’s first full month of sales to dispensaries in Nevada.

Dicerna Pharmaceuticals, Inc. will host an R&D Day today in New York City to discuss its pipeline of GalXC™-based RNAi therapeutic candidates.

GS-9674 Granted Orphan Drug Designation by the U.S. Food and Drug Administration

Mirati Therapeutics, Inc. announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C.

Obsidian Therapeutics, a biotechnology company developing cell therapies with pharmacologic operating systems, today announced the presentation of preclinical data demonstrating fine-tuned regulation of cytokine production and CAR-T function using Destabilizing Domains (DDs) paired with FDA-approved small molecule drugs.